RxDoctor Payments DataLook up a doctor →

Jose Moreno, MD

Urology · Pottstown, PANPI 1699768184

Payments from drug & device makers

$334,153in general payments, 2019–2025

Across 298 payments — averaging $1121.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$314K
  • Exact Sciences$12K
  • Bayer$881
  • Dendreon Pharmaceuticals LLC$761
  • Janssen Scientific Affairs, LLC$666
  • Ferring Pharmaceuticals Inc.$574
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$8,224100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$334,153 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$298,037
Medicare patients
776
Services billed
9,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide55$778,226
OrgovyxRelugolix230$742,502
XtandiEnzalutamide45$561,225
NubeqaDarolutamide12$153,119
MyrbetriqMirabegron162$119,150
GemtesaVibegron79$61,963
Abiraterone Acetate15$58,720
Methenamine Hippurate279$17,360
PremarinEstrogens, Conjugated34$14,856
Tamsulosin Hcl772$12,978
Silodosin78$7,312
Testosterone48$5,629
Finasteride352$4,894
Mirabegron ErMirabegron11$4,852
Oxybutynin Chloride ErOxybutynin Chloride121$2,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$165$804,466309 claims
Johnson & JohnsonErleada$355$778,22655 claims
Astellas Pharma US IncXtandi, Myrbetriq$333$680,374207 claims
BayerNubeqa$881$153,11912 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$666$58,72015 claims
PfizerPremarin$340$14,85634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.

Other urology in Pottstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →